Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulforaphane or rTMS add-on to Escitalopram for MDD
NCT05145270Phase 4Unknown
- Sponsor
- Shanghai Mental Health Center
- Start
- Nov 2019
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Phase 4, randomised trial (3 arms), sponsored by Shanghai Mental Health Center. Primary endpoint: Reduction rate in 17-Hamilton Depression Rating Scale total score at 12 weeks. Status: unknown.
Beyond the preview
Go deeper on NCT05145270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145270.